Compare $OTLC vs $SNTI | Chartloom

Compare

$OTLC vs $SNTI

Oncotelic Therapeutics Inc · Senti Biosciences Inc

OTLC

Oncotelic Therapeutics Inc

SNTI

Senti Biosciences Inc

Compare $OTLC vs $SNTI

Comparing Oncotelic Therapeutics Inc and Senti Biosciences Inc

OTLCOncotelic Therapeutics Inc

SNTISenti Biosciences Inc

OTLCOncotelic Therapeutics Inc

Market cap

$9M

P/E (TTM)

0.04x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.0%

52W performance

-76.9%

FCF yield

-16.5%

SNTISenti Biosciences Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-71.4%

52W performance

-82.3%

FCF yield

-388.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

OTLC

SNTI

Detailed metrics comparison

OTLC

Oncotelic Therapeutics Inc

SNTI

Senti Biosciences Inc

Market Cap

OTLC$9M

SNTI$10M

Enterprise Value

OTLC$23M

SNTI$7M

Price

OTLC$0.02

SNTI$0.31

P/E Ratio

OTLC0.04x

SNTIN/A

P/S Ratio

OTLC36.91x

SNTI178.01x

EV/Sales

OTLC91.75x

SNTI133.10x

EV/EBITDA

OTLC0.00x

SNTI0.00x

P/B Ratio

OTLC0.04x

SNTI3.91x

P/FCF Ratio

OTLCN/A

SNTIN/A

EV/FCF

OTLC-15.05x

SNTI-0.19x

PEG Ratio

OTLCN/A

SNTIN/A

Forward P/E (NTM)

OTLCN/A

SNTIN/A

Forward P/S (NTM)

OTLCN/A

SNTIN/A

Revenue (TTM)

OTLC$250K

SNTI$55K

Revenue Growth (YoY)

OTLCN/A

SNTIN/A

Forward Rev Growth

OTLC0.0%

SNTI-13.8%

Gross Margin (TTM)

OTLC83.1%

SNTI0.0%

Operating Margin (TTM)

OTLC0.0%

SNTI0.0%

EBITDA Margin (TTM)

OTLC-1545.3%

SNTI-97030.9%

Net Margin (TTM)

OTLC99875.6%

SNTI-90116.4%

FCF Margin (TTM)

OTLC-609.8%

SNTI-69183.6%

Net Income (TTM)

OTLC$250M

SNTI$-50M

FCF (TTM)

OTLC$-2M

SNTI$-38M

EPS (TTM)

OTLC$0.53

SNTI-$1.59

ROE (TTM)

OTLC139.7%

SNTI-50379.0%

ROA (TTM)

OTLC91.8%

SNTI-11312.0%

ROIC (TTM)

OTLC129.6%

SNTI-50379.0%

Cash

OTLC$186K

SNTI$6M

Debt

OTLC$14M

SNTI$4M

Net Cash/Debt

OTLC$-14M

SNTI$2M

Current Ratio (TTM)

OTLC0.08x

SNTI0.83x

Quick Ratio (TTM)

OTLC0.01x

SNTI0.47x

Debt/Equity (TTM)

OTLC0.05x

SNTI0.00x

Debt/Assets (TTM)

OTLC0.0%

SNTI0.0%

Interest Coverage (TTM)

OTLCN/A

SNTIN/A

Net Debt/EBITDA (TTM)

OTLC0.00x

SNTI0.00x

Beta

OTLC-0.07

SNTI2.28

52W Performance

OTLC-76.9%

SNTI-82.3%

YTD Performance

OTLC-74.0%

SNTI-71.4%

% from 52W High

OTLC-81.1%

SNTI-89.1%

% from 52W Low

OTLC4.0%

SNTI8.4%

Asset Turnover (TTM)

OTLC0.00x

SNTI0.00x

FCF Yield (TTM)

OTLC-16.5%

SNTI-388.7%

Earnings Yield (TTM)

OTLC2706.0%

SNTI-506.3%

Dividend Yield (TTM)

OTLCN/A

SNTIN/A

Rule of 40

OTLC-609.8

SNTI-69,183.6

EV/GP/RG

OTLCN/A

SNTIN/A

Ticker research

View OTLC research View SNTI research

Metric	OTLC Oncotelic Therapeutics Inc	SNTI Senti Biosciences Inc
Market & Valuation
Market Cap	$9M	$10M
Enterprise Value	$23M	$7M
Price	$0.02	$0.31
P/E Ratio	0.04x	N/A
P/S Ratio	36.91x	178.01x
EV/Sales	91.75x	133.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.04x	3.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.05x	-0.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$250K	$55K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	-13.8%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1545.3%	-97030.9%
Net Margin (TTM)	99875.6%	-90116.4%
FCF Margin (TTM)	-609.8%	-69183.6%
Net Income (TTM)	$250M	$-50M
FCF (TTM)	$-2M	$-38M
EPS (TTM)	$0.53	-$1.59
ROE (TTM)	139.7%	-50379.0%
ROA (TTM)	91.8%	-11312.0%
ROIC (TTM)	129.6%	-50379.0%
Financial Health
Cash	$186K	$6M
Debt	$14M	$4M
Net Cash/Debt	$-14M	$2M
Current Ratio (TTM)	0.08x	0.83x
Quick Ratio (TTM)	0.01x	0.47x
Debt/Equity (TTM)	0.05x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.07	2.28
52W Performance	-76.9%	-82.3%
YTD Performance	-74.0%	-71.4%
% from 52W High	-81.1%	-89.1%
% from 52W Low	4.0%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-16.5%	-388.7%
Earnings Yield (TTM)	2706.0%	-506.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-609.8	-69,183.6
EV/GP/RG	N/A	N/A
Ticker research	View OTLC research	View SNTI research

Valuation

P/E Ratio

OTLC

0.04x

P/S Ratio

OTLC

36.91x

SNTI

178.01x

EV/FCF

OTLC

-15.05x

SNTI

-0.19x

Growth & revenue

Forward Revenue Growth

OTLC

0.0%

SNTI

-13.8%

Profitability & performance

Gross Margin

OTLC

83.1%

SNTI

0.0%

ROE

OTLC

139.7%

SNTI

-50379.0%

FCF Yield %

OTLC

-16.5%

SNTI

-388.7%

52-Week Performance

OTLC

-76.9%

SNTI

-82.3%

Detailed metrics comparison

OTLC

Oncotelic Therapeutics Inc

SNTI

Senti Biosciences Inc

Market Cap

OTLC$9M

SNTI$10M

Enterprise Value

OTLC$23M

SNTI$7M

Price

OTLC$0.02

SNTI$0.31

P/E Ratio

OTLC0.04x

SNTIN/A

P/S Ratio

OTLC36.91x

SNTI178.01x

EV/Sales

OTLC91.75x

SNTI133.10x

EV/EBITDA

OTLC0.00x

SNTI0.00x

P/B Ratio

OTLC0.04x

SNTI3.91x

P/FCF Ratio

OTLCN/A

SNTIN/A

EV/FCF

OTLC-15.05x

SNTI-0.19x

PEG Ratio

OTLCN/A

SNTIN/A

Forward P/E (NTM)

OTLCN/A

SNTIN/A

Forward P/S (NTM)

OTLCN/A

SNTIN/A

Revenue (TTM)

OTLC$250K

SNTI$55K

Revenue Growth (YoY)

OTLCN/A

SNTIN/A

Forward Rev Growth

OTLC0.0%

SNTI-13.8%

Gross Margin (TTM)

OTLC83.1%

SNTI0.0%

Operating Margin (TTM)

OTLC0.0%

SNTI0.0%

EBITDA Margin (TTM)

OTLC-1545.3%

SNTI-97030.9%

Net Margin (TTM)

OTLC99875.6%

SNTI-90116.4%

FCF Margin (TTM)

OTLC-609.8%

SNTI-69183.6%

Net Income (TTM)

OTLC$250M

SNTI$-50M

FCF (TTM)

OTLC$-2M

SNTI$-38M

EPS (TTM)

OTLC$0.53

SNTI-$1.59

ROE (TTM)

OTLC139.7%

SNTI-50379.0%

ROA (TTM)

OTLC91.8%

SNTI-11312.0%

ROIC (TTM)

OTLC129.6%

SNTI-50379.0%

Cash

OTLC$186K

SNTI$6M

Debt

OTLC$14M

SNTI$4M

Net Cash/Debt

OTLC$-14M

SNTI$2M

Current Ratio (TTM)

OTLC0.08x

SNTI0.83x

Quick Ratio (TTM)

OTLC0.01x

SNTI0.47x

Debt/Equity (TTM)

OTLC0.05x

SNTI0.00x

Debt/Assets (TTM)

OTLC0.0%

SNTI0.0%

Interest Coverage (TTM)

OTLCN/A

SNTIN/A

Net Debt/EBITDA (TTM)

OTLC0.00x

SNTI0.00x

Beta

OTLC-0.07

SNTI2.28

52W Performance

OTLC-76.9%

SNTI-82.3%

YTD Performance

OTLC-74.0%

SNTI-71.4%

% from 52W High

OTLC-81.1%

SNTI-89.1%

% from 52W Low

OTLC4.0%

SNTI8.4%

Asset Turnover (TTM)

OTLC0.00x

SNTI0.00x

FCF Yield (TTM)

OTLC-16.5%

SNTI-388.7%

Earnings Yield (TTM)

OTLC2706.0%

SNTI-506.3%

Dividend Yield (TTM)

OTLCN/A

SNTIN/A

Rule of 40

OTLC-609.8

SNTI-69,183.6

EV/GP/RG

OTLCN/A

SNTIN/A

Ticker research

View OTLC research View SNTI research

Metric	OTLC Oncotelic Therapeutics Inc	SNTI Senti Biosciences Inc
Market & Valuation
Market Cap	$9M	$10M
Enterprise Value	$23M	$7M
Price	$0.02	$0.31
P/E Ratio	0.04x	N/A
P/S Ratio	36.91x	178.01x
EV/Sales	91.75x	133.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.04x	3.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-15.05x	-0.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$250K	$55K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	-13.8%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1545.3%	-97030.9%
Net Margin (TTM)	99875.6%	-90116.4%
FCF Margin (TTM)	-609.8%	-69183.6%
Net Income (TTM)	$250M	$-50M
FCF (TTM)	$-2M	$-38M
EPS (TTM)	$0.53	-$1.59
ROE (TTM)	139.7%	-50379.0%
ROA (TTM)	91.8%	-11312.0%
ROIC (TTM)	129.6%	-50379.0%
Financial Health
Cash	$186K	$6M
Debt	$14M	$4M
Net Cash/Debt	$-14M	$2M
Current Ratio (TTM)	0.08x	0.83x
Quick Ratio (TTM)	0.01x	0.47x
Debt/Equity (TTM)	0.05x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.07	2.28
52W Performance	-76.9%	-82.3%
YTD Performance	-74.0%	-71.4%
% from 52W High	-81.1%	-89.1%
% from 52W Low	4.0%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-16.5%	-388.7%
Earnings Yield (TTM)	2706.0%	-506.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-609.8	-69,183.6
EV/GP/RG	N/A	N/A
Ticker research	View OTLC research	View SNTI research